Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study
| Autor: | Pee-Win Chong, Barbara Grube, Ralf Uebelhack, Felix Alt |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Dietary Fiber Male medicine.medical_specialty lcsh:Internal medicine Article Subject Endocrinology Diabetes and Metabolism Placebo-controlled study Overweight Placebo law.invention Body Mass Index Randomized controlled trial Double-Blind Method Weight loss law Internal medicine Germany Weight Loss medicine Humans Obesity lcsh:RC31-1245 Cyclodextrins business.industry Body Weight Middle Aged Body Weight Maintenance Physical therapy Clinical Study Female Anti-Obesity Agents Plant Preparations medicine.symptom business Weight gain Body mass index |
| Zdroj: | Journal of Obesity Journal of Obesity, Vol 2015 (2015) |
| ISSN: | 2090-0708 |
| DOI: | 10.1155/2015/953138 |
| Popis: | Background.Litramine (IQP-G-002AS) was shown to be effective and safe for weight loss in overweight and obese subjects. However, long-term effectiveness on maintenance of body weight loss has yet to be ascertained.Objective.To assess effect of Litramine on maintenance of body weight loss.Methods.A double-blind, randomised, placebo-controlled trial on overweight and obese patients was conducted over two sites in Germany for 24 weeks. Subjects with documented previous weight loss of 3% over the last 3–6 months were randomised to groups given either Litramine (3 g/day) or a matching placebo. Primary endpoints were difference of mean body weight (kg) between baseline and end of study and maintenance of initially lost body weight in verum group, where maintenance is defined as ≤1% weight gain.Results.Subjects who were taking Litramine lost significantly more body weight compared to the subjects taking placebo who gained weight instead (-0.62±1.55 kg versus1.62±1.48 kg,p<0.001). More importantly, 92% of subjects in Litramine group were able to maintain their body weight after initial weight loss, versus 25% in placebo group. No serious adverse events were reported throughout.Conclusion.Litramine is effective and safe for long-term body weight maintenance.Trial Registration.This trial is registered with Clinicaltrials.gov identifier:NCT01505387. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|